Following a recommendation from the National Medicines Safety Agency (ANSM), which recommends limiting the supply of paracetamol in pharmacies, the laboratories that produce this painkiller want to be reassuring. “As for UPSA, which daily monitors the stock status of its references (Dafalgan, Efferalgan), no shortage has been observed.”the lab said in a letter to AFP.
On Wednesday, ANSM, the College of General Medicine and the pharmacists’ unions FSPF and USPO formulated “recommendations to moderate the use of paracetamol”and thus give patients who have an immediate need the opportunity to benefit from it.
They therefore recommend that pharmacists, in the absence of a prescription, limit dispensing to two boxes per patient. Another recommendation, this time for doctors: do not prescribe paracetamol to patients who do not have an immediate need.
One million boxes of Doliprane produced per day
However, the largest French producers insist that stocks are not sold out. “The weekly monitoring set up by the UPSA reports more than a month’s stock in pharmacies on average for the paracetamol brands Dafalgan and Efferalgan”emphasizes UPSA to Agence France-Presse.
85% of active ingredient supplies come from the USA. The manufacture of the finished product is then completely ensured at the laboratory’s industrial areas in France, in Agen, explains the manufacturer.
The giant Sanofi declares that it is not experiencing supply problems either. The group produces around 1 million boxes of Doliprane per day, which is enough to cover the population’s needs until the end of the year, he says. To meet exceptional demand, the Lisieux site (Calvados) “running at full capacity”adds the laboratory, which specifies that 96% of this production is intended for the French market.
At the height of the pandemic, the sale of paracetamol was limited to one box per person, which created a mini-panic and led to the decision to repatriate the production of its active ingredient to French territory. This will be produced again in Isère from 2023.